(Q33212476)

24 July 2017

1 reference

title

Chronic hepatitis C treatment patterns in African American patients: an update (English)

1 reference

24 July 2017

1 reference

1 reference

1 reference

Samuel Daniel

1

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

The American Journal of Gastroenterology

24 July 2017

published in

1 reference

24 July 2017

volume

100

1 reference

24 July 2017

issue

3

1 reference

24 July 2017

page(s)

716-722

1 reference

The burden of hepatitis C in the United States

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Viral heterogeneity of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Hepatitis C infection in African Americans: its natural history and histological progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Course and outcome of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Approach to the patient with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Association of diabetes mellitus and chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Racial differences in HLA class II associations with hepatitis C virus outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

MHC and the viral hepatitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Host genetic factors influence disease progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.41321.X

10.1111/J.1572-0241.2005.41321.X

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference